Steatotic liver disease in patients with chronic hepatitis C

Table 4 Characteristics of antiviral therapy and liver disease in the steatotic liver disease and non-steatotic liver disease groups, n (%)

Parameter	SLD (n = 290)	Non-SLD (n = 398)	P value
GT3	71 (24.5)	43 (10.8)	< 0.0001
History of antiviral therapy			0.0315
Treatment-naïve	257 (88.6)	380 (95.5)
Treatment-experienced, non-responder to IFN-based regimens	19 (6.6)	15 (3.8)
Treatment-experienced, non-responder to DAA regimens	14 (4.8)	3 (0.7)
Current treatment regimen			< 0.0001
GLE/PIB	127 (43.8)	245 (61.6)
SOF/VEL ± RBV	158 (54.5)	153 (38.4)
SOF/VEL/VOX	5 (1.7)	0
History of hepatic decompensation
Ascites and/or encephalopathy	25 (8.6)	8 (2.0)	0.0001
Ascites	24 (8.3)	8 (2)	0.0002
Encephalopathy	8 (2.7)	2 (0.5)	0.0209
Documented esophageal varices	38 (13.1)	17 (4.3)	< 0.0001
Liver decompensation at baseline
Ascites and/or encephalopathy	23 (7.9)	9 (2.3)	0.0005
Ascites	23 (7.9)	8 (2)	0.0003
Encephalopathy	11 (3.8)	3 (0.8)	0.0108
F4	104 (35.8)	48 (12)	< 0.0001
Child-Pugh, in relation to F4
B + C	30 (29.1)	12 (25)	0.0001
HCC	10 (3.4)	4 (1.0)	0.0299
OLTx	0	0	NA

SLD: Steatotic liver disease; GT3: Genotype 3; IFN: Interferon; DAA: Direct-acting antiviral; GLE/PIB: Glecaprevir/pibrentasvir; SOF/VEL: Sofosbuvir/velpatasvir; SOF/VEL ± RBV: Sofosbuvir/velpatasvir with or without ribavirin; F4: Fibrosis stage 4; HCC: Hepatocellular carcinoma; OLTx: Orthotopic liver transplantation.